Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Aug 13, 2025
- Accession no.
- 0001601830-25-000130
- Filed
- Aug 13, 2025
- Trade date
- Aug 11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $3.26M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | Class A Common Stock | CConversionAcquired | +423,666 | $0.00 | $0 | 1,504,919 | Direct | |
| Aug 11, 2025 | Class A Common Stock | SSaleDisposed | −500,300 | $5.28 | −$2,641,584 | 1,004,619 | Direct | |
| Aug 11, 2025 | Class A Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 994,619 | Direct | |
| Aug 11, 2025 | Class A Common Stock | CConversionAcquired | +100,000 | $0.00 | $0 | 100,000 | Indirect | |
| Aug 11, 2025 | Class A Common Stock | SSaleDisposed | −100,000 | $5.28 | −$528,000 | 0 | Indirect | |
| Aug 11, 2025 | Class A Common Stock | CConversionAcquired | +17,875 | $0.00 | $0 | 17,875 | Indirect | |
| Aug 11, 2025 | Class A Common Stock | SSaleDisposed | −17,875 | $5.28 | −$94,380 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | Class A Common Stock | CConversionDisposed | −423,666 | $0.00 | $0 | 5,473,034 | Direct | |
| Aug 11, 2025 | Class A Common Stock | CConversionDisposed | −100,000 | $0.00 | $0 | 386,000 | Indirect | |
| Aug 11, 2025 | Class A Common Stock | CConversionDisposed | −17,875 | $0.00 | $0 | 50,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.